Develops disease‑modifying RNA therapeutics (antagomirs) for cardiovascular and metabolic disorders, with a focus on treating diastolic heart failure. Lead candidates show in vivo proof‑of‑concept (three advanced antagomirs) that partially restore heart function, supported by patented technology and multiple follow‑on programs.